Pantoprazole (Protonix)

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Also Known As:

Protonix; BY 1023; BY-1023; Pantoprazole Sodium; SK&F 96022; SK&F-96022; SKF-96022; BY1023; SK&F96022; SKF 96022; SKF96022; 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-

Networked: 786 relevant articles (133 outcomes, 202 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Armstrong, D: 11 articles (06/2009 - 10/2001)
2.	Bardhan, K D: 11 articles (06/2007 - 01/2000)
3.	Marker, Søren: 10 articles (04/2022 - 12/2018)
4.	Perner, Anders: 10 articles (04/2022 - 12/2018)
5.	Krag, Mette: 9 articles (04/2022 - 12/2018)
6.	Comer, Gail M: 9 articles (08/2011 - 04/2006)
7.	Gatz, G: 9 articles (01/2007 - 01/2000)
8.	Gatz, Gudrun: 9 articles (01/2007 - 07/2003)
9.	Møller, Morten Hylander: 8 articles (04/2022 - 01/2019)
10.	Metz, D C: 8 articles (01/2007 - 01/2000)

Related Diseases

1.	Gastroesophageal Reflux (GERD) 01/01/2018 - "Pantoprazole also continuously improved the quality of life of GERD patients over 8 weeks of treatment and was very well tolerated throughout the whole study. " 04/01/2006 - "Pantoprazole (20 and 40 mg) is effective in reducing endoscopically proven GERD symptoms in children. " 04/01/2006 - "To evaluate symptom improvement in 53 children (aged 5-11 years) with endoscopically proven gastroesophageal reflux disease (GERD) treated with pantoprazole (10, 20 and 40 mg) using the GERD Assessment of Symptoms in Pediatrics Questionnaire. " 01/01/2014 - "Pantoprazole-Mg 40 mg significantly improved a broad range of esophageal and extra-esophageal GERD related symptoms including sleep disturbances, as well as well-being, in patients with daytime or night-time GERD, making it a good option for patients with GERD, especially when extra-esophageal and night-time symptoms are present." 06/01/2010 - "Pantoprazole significantly improved GERD symptom scores and was well tolerated. "
2.	Ulcer 10/01/1999 - "Maintenance treatment with pantoprazole 40 mg has been shown to keep most patients with aggressive or refractory ulcer and reflux disease in remission for up to 3 years. " 04/01/2022 - "In this secondary analysis of Stress Ulcer Prophylaxis in Intensive Care Unit (SUP-ICU) trial, we assessed 1-year outcomes in the pantoprazole vs. placebo groups. " 01/01/2022 - "Further studies of pantoprazole as a treatment/preventative for abomasal ulcers are warranted." 01/01/2019 - "In the subgroup of patients with Simplified Acute Physiology Score (SAPS) II > 53 in the Stress Ulcer Prophylaxis in Intensive Care Unit (SUP-ICU) trial, there was interaction (P = 0.049) suggesting increased mortality in patients allocated to pantoprazole as compared with placebo. " 10/01/2016 - "Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study."
3.	Pain (Aches) 11/01/2012 - "The aim of this study was to evaluate the immediate effect of IV pantoprazole in addition to the conventional GI cocktail in the relief of severe dyspeptic pain. " 01/01/2020 - "She was instructed to continue pantoprazole and pain medication and outpatient repeat esophagogastroduodenoscopy. " 11/01/2012 - "A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain." 07/01/2008 - "Epigastric pain relief was achieved after 28 days' treatment in 55% of pantoprazole recipients and 45% of placebo recipients (per-protocol [PP]: 58% and 47%, respectively). " 12/01/2012 - "On the other hand, in the non-pantoprazole group, mean hospital stay was 7.6 days, time taken to start oral intake was 71.4 hours, and time taken to pain relief was 61.8 hours. "
4.	Hemorrhage 01/01/2019 - "Intermittent dosing with pantoprazole is sufficient and cost-effective for the prevention of gastric ESD-related bleeding. " 04/01/2017 - "Intravenous pantoprazole 40 mg every 24 h or 12 h for 2 days after endoscopic resection was equally effective for the prevention of delayed bleeding." 08/30/2023 - "The ongoing trial Re-EValuating the Inhibition of Stress Erosions (REVISE) compares pantoprazole 40 mg IV to placebo on the primary efficacy outcome of clinically important GI bleeding and the primary safety outcome of 90-day mortality. " 04/01/2022 - "In the SUP-ICU trial, 3298 acutely admitted ICU patients at risk of GI bleeding were randomly allocated, stratified for site, to pantoprazole or placebo. " 04/01/2022 - "The effects of pantoprazole vs. placebo on 1-year outcomes, resource use and employment status in ICU patients at risk for gastrointestinal bleeding: a secondary analysis of the SUP-ICU trial."
5.	Duodenal Ulcer (Curling's Ulcer) 08/01/1995 - "Pantoprazole was shown to be a highly-effective and well-tolerated treatment for acute duodenal ulcer. " 07/01/1999 - "The efficacy of the third pump inhibitor--pantoprazole--in the short-term treatment of Chinese patients with duodenal ulcer." 11/13/2020 - "This study was performed to evaluate the role of carrot when administered concurrently with a conventional antiulcer treatment, pantoprazole, in alleviating gastric and duodenal ulcers in female experimental animals. " 07/01/1996 - "Mexican Study Group of Pantoprazole++ in Duodenal Ulcer]." 02/01/1994 - "Pantoprazole-Duodenal Ulcer-Study Group."

Related Drugs and Biologics

1.	Ranitidine (Zantac)
2.	Esomeprazole (Nexium)
3.	Omeprazole (Prilosec)
4.	Acids
5.	Lansoprazole (Prevacid)
6.	Proton Pump Inhibitors
7.	Clarithromycin (Biaxin)
8.	Amoxicillin (Wymox)
9.	Famotidine (Pepcid)
10.	Nizatidine (Axid)

Related Therapies and Procedures

1.	Therapeutics
2.	Endoscopic Hemostasis
3.	Ligation
4.	Aftercare (After-Treatment)
5.	Length of Stay